PH12017501864A1 - Compositions and methods for treating autism - Google Patents
Compositions and methods for treating autismInfo
- Publication number
- PH12017501864A1 PH12017501864A1 PH12017501864A PH12017501864A PH12017501864A1 PH 12017501864 A1 PH12017501864 A1 PH 12017501864A1 PH 12017501864 A PH12017501864 A PH 12017501864A PH 12017501864 A PH12017501864 A PH 12017501864A PH 12017501864 A1 PH12017501864 A1 PH 12017501864A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- compositions
- treating autism
- autism
- treating
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title abstract 2
- 208000020706 Autistic disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/686,545 US9308188B2 (en) | 2013-10-22 | 2015-04-14 | Compositions and methods for treating intestinal hyperpermeability |
| US15/059,602 US9763903B2 (en) | 2013-10-22 | 2016-03-03 | Compositions and methods for treating intestinal hyperpermeability |
| PCT/US2016/024432 WO2016167944A2 (en) | 2015-04-14 | 2016-03-28 | Compositions and methods for treating intestinal hyperpermeability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12017501864A1 true PH12017501864A1 (en) | 2018-03-05 |
Family
ID=57126753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017501864A PH12017501864A1 (en) | 2015-04-14 | 2017-10-11 | Compositions and methods for treating autism |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP4438059A3 (enExample) |
| JP (1) | JP6858131B2 (enExample) |
| KR (1) | KR20180015126A (enExample) |
| CN (1) | CN107835695B (enExample) |
| AU (1) | AU2016247301A1 (enExample) |
| BR (1) | BR112017022184A2 (enExample) |
| CA (1) | CA2982442A1 (enExample) |
| EA (1) | EA038339B1 (enExample) |
| IL (1) | IL254963A0 (enExample) |
| MX (1) | MX2017013176A (enExample) |
| PH (1) | PH12017501864A1 (enExample) |
| WO (1) | WO2016167944A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| JP2021530568A (ja) * | 2018-07-19 | 2021-11-11 | ヤモ・ファーマシューティカルズ・エルエルシー | 自閉症を処置するための組成物および方法 |
| WO2020018292A1 (en) * | 2018-07-19 | 2020-01-23 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| KR102726917B1 (ko) | 2019-02-01 | 2024-11-07 | 닥터레이몬드 랩(주) | 자폐증의 예측방법 |
| EP3968785A4 (en) | 2019-05-14 | 2023-01-11 | Tyme, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4165382A (en) * | 1977-10-17 | 1979-08-21 | Jose Pozuelo | Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine |
| WO2001078704A2 (en) * | 2000-04-13 | 2001-10-25 | Evans William T | Gaba substrate and the use thereof for treating cognitive and emotional disorders |
| WO2006039691A2 (en) * | 2004-10-01 | 2006-04-13 | The Research Foundation Of State University Of New York | Morphine and morphine precursors |
| US9949923B2 (en) * | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
| PL220308B1 (pl) * | 2011-06-03 | 2015-10-30 | Kobel Buys Krystyna | Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego |
| KR20190109564A (ko) * | 2012-01-03 | 2019-09-25 | 큐어마크, 엘엘씨 | 신경계 및 정신 장애의 행동 증상을 치료하는 방법 |
| US20130183263A1 (en) * | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
| US9326962B2 (en) * | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US20150111878A1 (en) * | 2013-10-22 | 2015-04-23 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
-
2016
- 2016-03-28 AU AU2016247301A patent/AU2016247301A1/en not_active Abandoned
- 2016-03-28 MX MX2017013176A patent/MX2017013176A/es unknown
- 2016-03-28 JP JP2017554262A patent/JP6858131B2/ja active Active
- 2016-03-28 KR KR1020177032439A patent/KR20180015126A/ko not_active Withdrawn
- 2016-03-28 BR BR112017022184A patent/BR112017022184A2/pt not_active IP Right Cessation
- 2016-03-28 WO PCT/US2016/024432 patent/WO2016167944A2/en not_active Ceased
- 2016-03-28 CA CA2982442A patent/CA2982442A1/en not_active Abandoned
- 2016-03-28 EP EP24180230.5A patent/EP4438059A3/en active Pending
- 2016-03-28 EP EP16714718.0A patent/EP3283115B1/en active Active
- 2016-03-28 EA EA201792278A patent/EA038339B1/ru unknown
- 2016-03-28 CN CN201680023669.XA patent/CN107835695B/zh active Active
-
2017
- 2017-10-10 IL IL254963A patent/IL254963A0/en unknown
- 2017-10-11 PH PH12017501864A patent/PH12017501864A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6858131B2 (ja) | 2021-04-14 |
| KR20180015126A (ko) | 2018-02-12 |
| IL254963A0 (en) | 2017-12-31 |
| EA038339B1 (ru) | 2021-08-11 |
| EP3283115C0 (en) | 2024-06-12 |
| WO2016167944A3 (en) | 2017-08-10 |
| JP2018511639A (ja) | 2018-04-26 |
| CN107835695B (zh) | 2021-07-09 |
| WO2016167944A8 (en) | 2017-11-02 |
| WO2016167944A2 (en) | 2016-10-20 |
| EP4438059A3 (en) | 2025-01-01 |
| EP4438059A2 (en) | 2024-10-02 |
| EP3283115B1 (en) | 2024-06-12 |
| CA2982442A1 (en) | 2016-10-20 |
| CN107835695A (zh) | 2018-03-23 |
| AU2016247301A1 (en) | 2017-10-26 |
| EA201792278A1 (ru) | 2018-04-30 |
| MX2017013176A (es) | 2018-01-30 |
| BR112017022184A2 (pt) | 2018-07-03 |
| EP3283115A2 (en) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| MX2021000077A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2018006239A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2018006398A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2018006399A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016529A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016564A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016525A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2017016560A (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| WO2016167944A3 (en) | Compositions and methods for treating autism |